matrigel

Subscribe to Selected New Research on matrigel

1249 relevant articles (17 outcomes, 85 trials/studies) found for this Bio-Agent

Description: commercially available product which consists of 60% laminin, 30% type 4 collagen, 5% nidogen, 3% heparin sulfate proteoglycan & 1% entactin; promotes neurite outgrowth in culture

Also Known As:

Matrigel

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shevchenko, A: 1 article (02/2008)
2.	Beninati, S: 1 article (02/2008)
3.	Provenzano, B: 1 article (02/2008)
4.	Lentini, A: 1 article (02/2008)
5.	Caraglia, M: 1 article (02/2008)
6.	Abbruzzese, A: 1 article (02/2008)
7.	Sodek, Katharine L: 1 article (01/2008)
8.	Ringuette, Maurice J: 1 article (01/2008)
9.	Wolf, Markus: 1 article (01/2008)
10.	Brown, Theodore J: 1 article (01/2008)

Related Diseases

1.	Neoplasms (Cancer) 07/01/1997 - "We conclude that important characteristics of the SF-767 tumor model, which may be important when evaluating efficacy of anticancer agents, are altered by Matrigel." 01/01/1996 - "Reconstituted components of tumor basement membrane (matrigel) have been found to improve the growth in nude mice of several types of human tumors originating outside the central nervous system when premixed with the tumor cells before subcutaneous inoculation. " 10/01/2009 - "In Matrigel Boyden chamber invasion and capillary morphogenesis studies, transfected clones reduced endothelial cell invasion and capillary tube formation, which were abolished by tumor cell populations expressing both molecules. " 07/01/2008 - "In this study, highly invasive tumor cell lines (designated A431-I, -II and -III) derived from parental A431 tumor cells (A431-P) were isolated by three successive passages through a Boyden chamber with matrigel-coated membrane support. " 01/01/2008 - "Influence of matrigel on biodistribution studies in cancer research." Order ALL the reference details at left...
2.	Severe Combined Immunodeficiency (SCID) 10/01/2007 - "To enhance safety, these cells were implanted subcutaneously in a Matrigel scaffold, and the efficacy of this strategy was compared with i.v. delivery of engineered BOECs in nonhemophilic nonobese diabetic/severe combined immunodeficiency mice. " 04/01/2004 - "Finally, studies in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice demonstrated that human circulating EPCs are able to colonize a Matrigel plug. " 02/01/2009 - "Moreover, the peptide 4.10 inhibited the in vitro endothelial cell motility and organization into capillary-like structures, and the in vivo angiogenesis of human umbilical cord-derived endothelial cells implanted in Matrigel in severe combined immunodeficiency mice. " 12/01/2005 - "Moreover, these cells colonized a Matrigel plug in immunodeficient mice (NOD/SCID). " 11/01/1998 - "To test the in vivo activity of the expanded CIK cells, CML was engrafted into severe combined immunodeficiency disease (SCID) mice using matrigel. " Order ALL the reference details at left...
3.	Breast Neoplasms (Breast Cancer) 07/01/2005 - "The present study was undertaken to characterize the signal transduction mechanisms underlying this serum deprivation-dependent activation of both the NHE1 and the concomitant invasive characteristics such as leading edge pseudopodia development and penetration of matrigel in breast cancer cell lines representing different stages of metastatic progression. " 05/01/2009 - "The matrigel penetrating ability of human breast cancer cells was examined in vitro experiments. " 03/01/2009 - "Furthermore, a Matrigel invasion assay with breast cancer cell lines and a transformation assay in mouse JB6 cells revealed that TPA-induced invasion and transformation responses were completely repressed by this compound. " 01/01/2008 - "CONCLUSION: We report the novel findings that JS-K inhibits breast cancer invasion across the Matrigel basement membrane, and NO production is vital for this activity. " 01/01/2008 - "RESULTS: Under conditions by which JS-K was not cytotoxic, JS-K significantly decreased (P < 0.05) the invasiveness of breast cancer cells across the Matrigel basement membrane, which was directly correlated with NO production. " Order ALL the reference details at left...
4.	Neoplasm Metastasis (Metastasis) 12/01/2007 - "Invasion through Matrigel and migration in wound-healing assays, in vitro correlates of metastasis, are significantly greater in VHL mutant RCC compared with wild-type cells, and blocked by dominant-negative JAK expression or JAK inhibitors. " 11/01/2009 - "Matrigel invasion and cell migration assays were done to investigate the BMP7-induced metastasis inhibition ability. " 12/04/2008 - "Here we show that transfection of noninvasive R37 cells with an expression vector for RAN resulted in increased anchorage-independent growth, cell attachment and invasion through Matrigel in vitro, and metastasis in syngeneic rats. " 12/01/2008 - "GA caused a concentration-dependent suppression of cell invasion through Matrigel and significantly inhibited lung metastases of the cells transplanted in vivo. " 04/01/2008 - "In conclusion, the orthotopic implantation mice model with Matrigel was useful, and we isolated candidate genes such as RNF125 that possibly play an important role in LN metastasis of CRC cells." Order ALL the reference details at left...
5.	Prostatic Neoplasms (Prostate Cancer) 09/01/1992 - "Also, we report an improved method for obtaining an increased growth of human prostate cancer cells in nude mice by injecting these cells in Matrigel. " 02/01/2006 - "The Matrigel invasion assay was used to study the influence of uPA inhibitors on the invasive potential of prostate cancer cell lines. " 02/04/2005 - "In this study, we found that Du145 prostate cancer cells underwent morphogenesis on the reconstituted basement membrane Matrigel to form an anastomosing network of multicellular structures. " 08/06/2009 - "CST6 overexpression in human prostate cancer cells significantly reduced in vitro cell proliferation and matrigel invasion. " 09/01/2007 - "Nude mice were subcutaneously injected with Matrigel impregnated with LNCaP prostate cancer cells. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Carbon Monoxide
2.	Fibronectins (Fibronectin)
3.	Estrogens (Estrogen)
4.	Vitronectin
5.	contortrostatin
6.	Snake Venoms (Snake Venom)
7.	Laminin (Merosin)
8.	glucuronyl glucosamine glycan sulfate (Vessel)
9.	Tea
10.	Tissue Inhibitor of Metalloproteinase-2

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Subcutaneous Injections
3.	Intravenous Injections
4.	Transplantation (Transplant Recipients)
5.	Transplants (Transplant)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>